| D007223 |
Infant |
A child between 1 and 23 months of age. |
Infants |
|
| D008297 |
Male |
|
Males |
|
| D009928 |
Organ Specificity |
Characteristic restricted to a particular organ of the body, such as a cell type, metabolic response or expression of a particular protein or antigen. |
Tissue Specificity,Organ Specificities,Specificities, Organ,Specificities, Tissue,Specificity, Organ,Specificity, Tissue,Tissue Specificities |
|
| D012074 |
Remission Induction |
Therapeutic act or process that initiates a response to a complete or partial remission level. |
Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions |
|
| D003520 |
Cyclophosphamide |
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. |
(+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271 |
|
| D006391 |
Hemangioma |
A vascular anomaly due to proliferation of BLOOD VESSELS that forms a tumor-like mass. The common types involve CAPILLARIES and VEINS. It can occur anywhere in the body but is most frequently noticed in the SKIN and SUBCUTANEOUS TISSUE. (from Stedman, 27th ed, 2000) |
Angioma,Chorioangioma,Hemangioma, Histiocytoid,Hemangioma, Intramuscular,Chorangioma,Chorangiomas,Chorioangiomas,Hemangiomas,Hemangiomas, Histiocytoid,Hemangiomas, Intramuscular,Histiocytoid Hemangioma,Histiocytoid Hemangiomas,Intramuscular Hemangioma,Intramuscular Hemangiomas |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D015080 |
Mesna |
A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. |
2-Mercaptoethanesulfonate,Coenzyme M,Ethanesulfonic acid, 2-mercapto-, monosodium salt,ASTA-D 7093,MESNA-cell,Mesnex,Mesnum,Mistabron,Mistabronco,Mitexan,Mucofluid,Sodium 2-Mercaptoethanesulphonate,UCB-3983,Uromitexan,Ziken,2 Mercaptoethanesulfonate,2-Mercaptoethanesulphonate, Sodium,ASTA D 7093,ASTAD 7093,MESNA cell,UCB 3983,UCB3983 |
|
| D018906 |
Antineoplastic Agents, Alkylating |
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) |
Alkylating Agents, Antineoplastic,Alkylating Antineoplastic Agents,Alkylating Antineoplastic Drugs,Alkylating Antineoplastics,Alkylating Drugs, Antineoplastic,Antineoplastic Alkylating Agents,Antineoplastic Drugs, Alkylating,Antineoplastics, Alkylating,Antineoplastic Alkylating Drugs,Drugs, Antineoplastic Alkylating |
|
| D020011 |
Protective Agents |
Synthetic or natural substances which are given to prevent a disease or disorder or are used in the process of treating a disease or injury due to a poisonous agent. |
Protective Agent,Protective Drug,Protective Drugs,Agent, Protective,Agents, Protective,Drug, Protective,Drugs, Protective |
|
-transparent.png){kind=logo}
